☰

cached image

Kim A. Neve, Ph.D. - Publications

Affiliations: 
Portland VA Medical Center, United States 
Area:
Dopamine receptors, signal transduction, cellular and molecular biology of G protein-coupled receptors, structure-function analysis of dopamine receptors, behavioral
Website:
http://www.ohsu.edu/xd/education/schools/school-of-medicine/academic-programs/graduate-studies/faculty/grad-studies-faculty.cfm?facultyid=268
Tree Info Grants Similar researchers PubMed Report error

102 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Rodriguez-Contreras D, García-Nafría J, Chan AE, Shinde U, Neve KA. Comparison of the function of two novel human dopamine D2 receptor variants identifies a likely mechanism for their pathogenicity. Biochemical Pharmacology. 116228. PMID 38643909 DOI: 10.1016/j.bcp.2024.116228  0.441
2022 Rodriguez-Contreras D, Gong S, Lebowitz JJ, Fedorov LM, Asad N, Dore TM, Phillips TJ, Ford CP, Williams JT, Neve KA. Gait Abnormalities and Aberrant D2 Receptor Expression and Signaling in Mice Carrying the Human Pathogenic Mutation . Molecular Pharmacology. PMID 36456191 DOI: 10.1124/molpharm.122.000606  0.372
2021 Lee HJ, Rodriguez-Contreras D, Neve KA. Commentary on "Novel Interaction of the Dopamine D2 Receptor and the Ca Binding Protein S100B: Role in D2 Receptor Function". Molecular Pharmacology. PMID 34045267 DOI: 10.1124/molpharm.121.000284  0.417
2021 Rodriguez-Contreras D, Condon AF, Buck DC, Asad N, Dore TM, Verbeek DS, Tijssen MAJ, Shinde U, Williams JT, Neve KA. Signaling-Biased and Constitutively Active Dopamine D2 Receptor Variant. Acs Chemical Neuroscience. PMID 33974399 DOI: 10.1021/acschemneuro.0c00712  0.473
2020 van der Weijden MCM, Rodriguez-Contreras D, Delnooz CCS, Robinson BG, Condon AF, Kielhold ML, Stormezand GN, Ma KY, Dufke C, Williams JT, Neve KA, Tijssen MAJ, Verbeek DS. A Gain-of-Function Variant in Dopamine D2 Receptor and Progressive Chorea and Dystonia Phenotype. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33200438 DOI: 10.1002/mds.28385  0.402
2019 Stafford AM, Reed C, Baba H, Walter NA, Mootz JR, Williams RW, Neve KA, Fedorov LM, Janowsky AJ, Phillips TJ. gene variants have a causal role in methamphetamine intake and response and interact with . Elife. 8. PMID 31274109 DOI: 10.7554/Elife.46472  0.314
2019 Beaulieu J, Borrelli E, Carlsson A, Caron MG, Civelli O, Espinoza S, Fisone G, Gainetdinov RR, Grandy DK, Kebabian JW, Langer SZ, Missale MC, Neve KA, Scatton B, Schwartz J, et al. Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Iuphar/Bps Guide to Pharmacology Cite. 2019. DOI: 10.2218/gtopdb/f20/2019.4  0.403
2018 Donthamsetti P, Gallo EF, Buck DC, Stahl EL, Zhu Y, Lane JR, Bohn LM, Neve KA, Kellendonk C, Javitch JA. Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation. Molecular Psychiatry. PMID 30120413 DOI: 10.1038/S41380-018-0212-4  0.516
2017 Robinson BG, Condon AF, Radl D, Borrelli E, Williams JT, Neve KA. Cocaine-induced adaptation of dopamine D2S, but not D2L autoreceptors. Elife. 6. PMID 29154756 DOI: 10.7554/Elife.31924  0.498
2017 Robinson BG, Bunzow JR, Grimm JB, Lavis LD, Dudman JT, Brown J, Neve KA, Williams JT. Desensitized D2 autoreceptors are resistant to trafficking. Scientific Reports. 7: 4379. PMID 28663556 DOI: 10.1038/S41598-017-04728-Z  0.546
2017 Robinson BG, Condon AF, Radl D, Borrelli E, Williams JT, Neve KA. Author response: Cocaine-induced adaptation of dopamine D2S, but not D2L autoreceptors Elife. DOI: 10.7554/Elife.31924.011  0.37
2016 Abraham AD, Neve KA, Matthew Lattal K. Effects of D1 receptor knockout on fear and reward learning. Neurobiology of Learning and Memory. PMID 27423521 DOI: 10.1016/J.Nlm.2016.07.010  0.464
2016 Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, Belknap JK, Eshleman AJ, Phillips TJ, Janowsky A. Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function. Plos One. 11: e0152581. PMID 27031617 DOI: 10.1371/Journal.Pone.0152581  0.427
2016 Abraham AD, Neve KA, Lattal KM. Activation of D1/5 Dopamine Receptors: A Common Mechanism for Enhancing Extinction of Fear and Reward-Seeking Behaviors. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26763483 DOI: 10.1038/Npp.2016.5  0.452
2015 Gantz SC, Robinson BG, Buck DC, Bunzow JR, Neve RL, Williams JT, Neve KA. Distinct regulation of dopamine D2S and D2L autoreceptor signaling by calcium. Elife. 4. PMID 26308580 DOI: 10.7554/Elife.09358  0.489
2015 Vanderwerf SM, Buck DC, Wilmarth PA, Sears LM, David LL, Morton DB, Neve KA. Role for Rab10 in Methamphetamine-Induced Behavior. Plos One. 10: e0136167. PMID 26291453 DOI: 10.1371/Journal.Pone.0136167  0.45
2015 Gantz SC, Levitt ES, Llamosas N, Neve KA, Williams JT. Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA. Cell Reports. 12: 944-54. PMID 26235617 DOI: 10.1016/J.Celrep.2015.07.005  0.416
2015 Zhen J, Antonio T, Ali S, Neve KA, Dutta AK, Reith ME. Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTPγS assays. Journal of Neuroscience Methods. 248: 7-15. PMID 25840364 DOI: 10.1016/J.Jneumeth.2015.03.028  0.54
2015 Gantz SC, Robinson BG, Buck DC, Bunzow JR, Neve RL, Williams JT, Neve KA. Author response: Distinct regulation of dopamine D2S and D2L autoreceptor signaling by calcium Elife. DOI: 10.7554/Elife.09358.016  0.374
2014 Clayton CC, Donthamsetti P, Lambert NA, Javitch JA, Neve KA. Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor. The Journal of Biological Chemistry. 289: 33663-75. PMID 25336643 DOI: 10.1074/Jbc.M114.605378  0.527
2014 Rangel-Barajas C, Malik M, Taylor M, Neve KA, Mach RH, Luedtke RR. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. Journal of Neurochemistry. 131: 418-31. PMID 25041389 DOI: 10.1111/Jnc.12825  0.569
2014 Abraham AD, Neve KA, Lattal KM. Dopamine and extinction: a convergence of theory with fear and reward circuitry. Neurobiology of Learning and Memory. 108: 65-77. PMID 24269353 DOI: 10.1016/J.Nlm.2013.11.007  0.362
2013 Neve KA, Ford CP, Buck DC, Grandy DK, Neve RL, Phillips TJ. Normalizing dopamine D2 receptor-mediated responses in D2 null mutant mice by virus-mediated receptor restoration: comparing D2L and D2S. Neuroscience. 248: 479-87. PMID 23811070 DOI: 10.1016/J.Neuroscience.2013.06.035  0.531
2011 Gantz SC, Ford CP, Neve KA, Williams JT. Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 12629-37. PMID 21880923 DOI: 10.1523/Jneurosci.0684-11.2011  0.378
2011 Neve K, Sibley DR. D2-like dopamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60156-4  0.441
2011 Neve K, Sibley DR. D3 dopamine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60154-0  0.44
2011 Sibley DR, Neve K. D1 dopamine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60153-9  0.44
2011 Sibley DR, Neve K. D1-like dopamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60152-7  0.441
2009 Lan H, Teeter MM, Gurevich VV, Neve KA. An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors. Molecular Pharmacology. 75: 19-26. PMID 18820126 DOI: 10.1124/Mol.108.050542  0.533
2009 Lan H, Liu Y, Bell MI, Gurevich VV, Neve KA. A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding. Molecular Pharmacology. 75: 113-23. PMID 18809670 DOI: 10.1124/Mol.108.050534  0.555
2008 Liu Y, Buck DC, Neve KA. Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Molecular Pharmacology. 74: 371-8. PMID 18445708 DOI: 10.1124/Mol.108.044925  0.581
2007 Liu Y, Buck DC, Macey TA, Lan H, Neve KA. Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling. Journal of Receptor and Signal Transduction Research. 27: 47-65. PMID 17365509 DOI: 10.1080/10799890601094152  0.567
2006 Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH, Zhang GC, Parelkar NK, Fibuch EE, Haines M, Neve KA, Liu F, Xiong ZG, Wang JQ. Modulation of D2R-NR2B interactions in response to cocaine. Neuron. 52: 897-909. PMID 17145509 DOI: 10.1016/J.Neuron.2006.10.011  0.456
2006 Neve KA. Novel features of G protein-coupled receptor kinase 4. Molecular Pharmacology. 69: 673-6. PMID 16339846 DOI: 10.1124/Mol.105.021535  0.406
2006 Liu Y, Teeter MM, DuRand CJ, Neve KA. Identification of a Zn2+-binding site on the dopamine D2 receptor. Biochemical and Biophysical Research Communications. 339: 873-9. PMID 16332354 DOI: 10.1016/J.Bbrc.2005.11.110  0.464
2006 Lan H, Durand CJ, Teeter MM, Neve KA. Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors. Molecular Pharmacology. 69: 185-94. PMID 16236817 DOI: 10.1124/Mol.105.017244  0.523
2005 Watts VJ, Neve KA. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacology & Therapeutics. 106: 405-21. PMID 15922020 DOI: 10.1016/J.Pharmthera.2004.12.005  0.672
2005 Wang C, Buck DC, Yang R, Macey TA, Neve KA. Dopamine D2 receptor stimulation of mitogen-activated protein kinases mediated by cell type-dependent transactivation of receptor tyrosine kinases. Journal of Neurochemistry. 93: 899-909. PMID 15857393 DOI: 10.1111/J.1471-4159.2005.03055.X  0.538
2005 Macey TA, Liu Y, Gurevich VV, Neve KA. Dopamine D1 receptor interaction with arrestin3 in neostriatal neurons. Journal of Neurochemistry. 93: 128-34. PMID 15773912 DOI: 10.1111/J.1471-4159.2004.02998.X  0.539
2004 Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. Journal of Receptor and Signal Transduction Research. 24: 165-205. PMID 15521361 DOI: 10.1081/Rrs-200029981  0.539
2004 Torvinen M, Kozell LB, Neve KA, Agnati LF, Fuxe K. Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor. Journal of Molecular Neuroscience : Mn. 24: 173-80. PMID 15456930 DOI: 10.1385/Jmn:24:2:173  0.559
2004 Macey TA, Gurevich VV, Neve KA. Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Molecular Pharmacology. 66: 1635-42. PMID 15361545 DOI: 10.1124/Mol.104.001495  0.553
2003 Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferré S, Lluis C, Bouvier M, Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. The Journal of Biological Chemistry. 278: 46741-9. PMID 12933819 DOI: 10.1074/Jbc.M306451200  0.52
2002 Mason JN, Kozell LB, Neve KA. Regulation of dopamine D(1) receptor trafficking by protein kinase A-dependent phosphorylation. Molecular Pharmacology. 61: 806-16. PMID 11901220 DOI: 10.1124/Mol.61.4.806  0.535
2001 Janowsky A, Neve K, Eshleman AJ. Uptake and release of neurotransmitters. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit7.9. PMID 18428535 DOI: 10.1002/0471142301.Ns0709S02  0.327
2001 Watts VJ, Taussig R, Neve RL, Neve KA. Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Galphas: characterization of Galphas-insensitive mutants of adenylyl cyclase V. Molecular Pharmacology. 60: 1168-72. PMID 11723222 DOI: 10.1124/Mol.60.6.1168  0.697
2001 Nelson CS, Ikeda M, Gompf HS, Robinson ML, Fuchs NK, Yoshioka T, Neve KA, Allen CN. Regulation of melatonin 1a receptor signaling and trafficking by asparagine-124. Molecular Endocrinology (Baltimore, Md.). 15: 1306-17. PMID 11463855 DOI: 10.1210/Mend.15.8.0681  0.469
2001 Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Molecular Pharmacology. 60: 373-81. PMID 11455025 DOI: 10.1124/Mol.60.2.373  0.771
2000 Wilcox RE, Huang WH, Brusniak MY, Wilcox DM, Pearlman RS, Teeter MM, DuRand CJ, Wiens BL, Neve KA. CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors. Journal of Medicinal Chemistry. 43: 3005-19. PMID 10956209 DOI: 10.1021/Jm990526Y  0.444
2000 Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, Mader SL. Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity. Clinical and Experimental Pharmacology & Physiology. 27: 9-13. PMID 10696522 DOI: 10.1046/J.1440-1681.2000.03210.X  0.739
1999 Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. The Journal of Pharmacology and Experimental Therapeutics. 289: 877-85. PMID 10215666  0.753
1999 Watts VJ, Vu MN, Wiens BL, Jovanovic V, Van Tol HH, Neve KA. Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors. Psychopharmacology. 141: 83-92. PMID 9952069 DOI: 10.1007/S002130050810  0.724
1998 Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 8692-9. PMID 9786976  0.795
1998 Wilcox RE, Tseng T, Brusniak MY, Ginsburg B, Pearlman RS, Teeter M, DuRand C, Starr S, Neve KA. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. Journal of Medicinal Chemistry. 41: 4385-99. PMID 9784114 DOI: 10.1021/Jm9800292  0.525
1998 Luo Y, Kokkonen GC, Wang X, Neve KA, Roth GS. D2 dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive G proteins and Ras-involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells. Journal of Neurochemistry. 71: 980-90. PMID 9721723 DOI: 10.1046/J.1471-4159.1998.71030980.X  0.531
1998 Johnson RA, Eshleman AJ, Meyers T, Neve KA, Janowsky A. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse (New York, N.Y.). 30: 97-106. PMID 9704886 DOI: 10.1002/(Sici)1098-2396(199809)30:1<97::Aid-Syn12>3.0.Co;2-M  0.359
1998 Wiens BL, Nelson CS, Neve KA. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Molecular Pharmacology. 54: 435-44. PMID 9687586 DOI: 10.1124/Mol.54.2.435  0.582
1998 Song S, Wang Y, Bak SY, During MJ, Bryan J, Ashe O, Ullrey DB, Trask LE, Grant FD, O'Malley KL, Riedel H, Goldstein DS, Neve KA, LaHoste GJ, Marshall JF, et al. Modulation of rat rotational behavior by direct gene transfer of constitutively active protein kinase C into nigrostriatal neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 4119-32. PMID 9592092 DOI: 10.1523/Jneurosci.18-11-04119.1998  0.494
1998 Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective Activation of Gαoby D2LDopamine Receptors in NS20Y Neuroblastoma Cells The Journal of Neuroscience. 18: 8692-8699. DOI: 10.1523/Jneurosci.18-21-08692.1998  0.789
1998 Song S, Wang Y, Bak S, During MJ, Bryan J, Ashe O, Ullrey DB, Trask LE, Grant FD, O’Malley KL, Riedel H, Goldstein DS, Neve KA, LaHoste GJ, Marshall JF, et al. Modulation of Rat Rotational Behavior by Direct Gene Transfer of Constitutively Active Protein Kinase C into Nigrostriatal Neurons The Journal of Neuroscience. 18: 4119-4132. DOI: 10.1523/JNEUROSCI.18-11-04119.1998  0.353
1997 Kozell LB, Neve KA. Constitutive activity of a chimeric D2/D1 dopamine receptor. Molecular Pharmacology. 52: 1137-49. PMID 9396784 DOI: 10.1124/Mol.52.6.1137  0.527
1997 Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, Neve KA. Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. Journal of Neurochemistry. 69: 1459-66. PMID 9326274 DOI: 10.1046/J.1471-4159.1997.69041459.X  0.343
1997 Watts VJ, Neve KA. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Molecular Pharmacology. 52: 181-6. PMID 9271339 DOI: 10.1124/Mol.52.2.181  0.725
1997 Neve K. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors: Commentary [1] Neuropsychopharmacology. 16: 111-113. DOI: 10.1016/S0893-133X(96)00188-1  0.543
1996 Watts VJ, Neve KA. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Molecular Pharmacology. 50: 966-76. PMID 8863843  0.724
1996 Brusniak MY, Pearlman RS, Neve KA, Wilcox RE. Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors. Journal of Medicinal Chemistry. 39: 850-9. PMID 8632409 DOI: 10.1021/jm950447w  0.328
1995 Cox BA, Rosser MP, Kozlowski MR, Duwe KM, Neve RL, Neve KA. Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse (New York, N.Y.). 21: 1-9. PMID 8525456 DOI: 10.1002/Syn.890210102  0.554
1995 Neve KA, Wiens BL. Four ways of being an agonist: multiple sequence determinants of efficacy at D2 dopamine receptors. Biochemical Society Transactions. 23: 112-6. PMID 7758672  0.404
1995 Starr S, Kozell LB, Neve KA. Drug-induced up-regulation of dopamine D2 receptors on cultured cells. Journal of Neurochemistry. 65: 569-77. PMID 7616211 DOI: 10.1046/J.1471-4159.1995.65020569.X  0.545
1995 Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology. 118: 401-9. PMID 7568626 DOI: 10.1007/Bf02245940  0.727
1995 Neve KA, Rosser MP, Barber DL. [12] Regulation of Na+-H+ exchange by G protein-coupled receptors Methods in Neurosciences. 25: 225-241. DOI: 10.1016/S1043-9471(05)80042-4  0.522
1995 Neve RL, Neve KA. [9] Receptor expression in mammalian cells Methods in Neurosciences. 25: 163-174. DOI: 10.1016/S1043-9471(05)80039-4  0.541
1994 Kozell LB, Machida CA, Neve RL, Neve KA. Chimeric D1/D2 dopamine receptors. Distinct determinants of selective efficacy, potency, and signal transduction. The Journal of Biological Chemistry. 269: 30299-306. PMID 7982941  0.397
1993 Ivins KJ, Neve KA, Feller DJ, Fidel SA, Neve RL. Antisense GAP-43 inhibits the evoked release of dopamine from PC12 cells. Journal of Neurochemistry. 60: 626-33. PMID 8419540 DOI: 10.1111/J.1471-4159.1993.Tb03194.X  0.368
1993 Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB. Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. European Journal of Pharmacology. 239: 271-3. PMID 8223910 DOI: 10.1016/0014-2999(93)91012-C  0.71
1993 Neve RL, Ivins KJ, Neve KA, Bahr BA, Vanderklish PW, Arai A, Lynch G. The Use of Antisense Intervention to Decipher the Role of the Neuronal Growth-Associated Protein GAP-43 Neuroprotocols. 2: 39-49. DOI: 10.1006/Ncmn.1993.1007  0.361
1992 Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, Belknap JK. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. The Journal of Pharmacology and Experimental Therapeutics. 261: 1282-90. PMID 1534844  0.429
1992 Machida CA, Searles RP, Nipper V, Brown JA, Kozell LB, Neve KA. Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene. Molecular Pharmacology. 41: 652-9. PMID 1533268  0.394
1992 Neve KA, Kozlowski MR, Rosser MP. Dopamine D2 receptor stimulation of Na+/H+ exchange assessed by quantification of extracellular acidification. The Journal of Biological Chemistry. 267: 25748-53. PMID 1361188  0.478
1992 Cox BA, Henningsen RA, Spanoyannis A, Neve RL, Neve KA. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. Journal of Neurochemistry. 59: 627-35. PMID 1321233 DOI: 10.1111/J.1471-4159.1992.Tb09416.X  0.559
1991 Neve KA. Regulation of dopamine D2 receptors by sodium and pH. Molecular Pharmacology. 39: 570-8. PMID 2017157  0.369
1991 Neve KA, Cox BA, Henningsen RA, Spanoyannis A, Neve RL. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Molecular Pharmacology. 39: 733-9. PMID 1828858  0.429
1991 Neve KA, Neve RL, Fidel S, Janowsky A, Higgins GA. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proceedings of the National Academy of Sciences of the United States of America. 88: 2802-6. PMID 1826366 DOI: 10.1073/Pnas.88.7.2802  0.478
1990 Neve KA, Henningsen RA, Kinzie JM, De Paulis T, Schmidt DE, Kessler RM, Janowsky A. Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand. The Journal of Pharmacology and Experimental Therapeutics. 252: 1108-16. PMID 2138666  0.489
1990 Albert PR, Neve KA, Bunzow JR, Civelli O. Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion. The Journal of Biological Chemistry. 265: 2098-104. PMID 1688845  0.49
1989 Neve KA, Henningsen RA, Bunzow JR, Civelli O. Functional characterization of a rat dopamine D-2 receptor cDNA expressed in a mammalian cell line. Molecular Pharmacology. 36: 446-51. PMID 2571073  0.501
1988 Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 336: 783-7. PMID 2974511 DOI: 10.1038/336783A0  0.556
1988 Luedtke RR, Korner M, Neve KA, Molinoff PB. Monoclonal antibodies with high affinity for spiroperidol. Journal of Neurochemistry. 50: 1253-62. PMID 2964511 DOI: 10.1111/J.1471-4159.1988.Tb10602.X  0.591
1988 Abramson SN, Martin MW, Hughes AR, Harden TK, Neve KA, Barrett DA, Molinoff PB. Interaction of beta-adrenergic receptors with the inhibitory guanine nucleotide-binding protein of adenylate cyclase in membranes prepared from cyc- S49 lymphoma cells. Biochemical Pharmacology. 37: 4289-97. PMID 2848525 DOI: 10.1016/0006-2952(88)90609-0  0.675
1986 Neve KA, Molinoff PB. Turnover of beta 1- and beta 2-adrenergic receptors after down-regulation or irreversible blockade. Molecular Pharmacology. 30: 104-11. PMID 3016496  0.593
1986 Neve KA, McGonigle P, Molinoff PB. Quantitative analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors. The Journal of Pharmacology and Experimental Therapeutics. 238: 46-53. PMID 3014123  0.582
1986 McGonigle P, Neve KA, Molinoff PB. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Molecular Pharmacology. 30: 329-37. PMID 2876374  0.605
1986 Neve KA, Molinoff PB. Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. The American Journal of Cardiology. 57: 17F-22F. PMID 2871741 DOI: 10.1016/0002-9149(86)90883-0  0.626
1985 Neve KA, Loeschen S, Marshall JF. Denervation accelerates the reappearance of neostriatal D-2 receptors after irreversible receptor blockade. Brain Research. 329: 225-31. PMID 3156659 DOI: 10.1016/0006-8993(85)90528-1  0.612
1985 Neve KA, Barrett DA, Molinoff PB. Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists. The Journal of Pharmacology and Experimental Therapeutics. 235: 657-64. PMID 2867205  0.602
1984 Altar CA, Walter RJ, Neve KA, Marshall JF. Computer-assisted video analysis of [3H]spiroperidol binding autoradiographs. Journal of Neuroscience Methods. 10: 173-88. PMID 6738107 DOI: 10.1016/0165-0270(84)90054-2  0.453
1984 Neve KA, Altar CA, Wong CA, Marshall JF. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury. Brain Research. 302: 9-18. PMID 6428705 DOI: 10.1016/0006-8993(84)91280-0  0.592
1984 Neve KA, Marshall JF. The effects of denervation and chronic haloperidol treatment on neostriatal dopamine receptor density are not additive in the rat. Neuroscience Letters. 46: 77-83. PMID 6203067 DOI: 10.1016/0304-3940(84)90202-7  0.53
1983 Altar A, Neve KA, Loughlin SE, Marshall JF, Fallon JH. The crossed mesostriatal projection: neurochemistry and developmental response to lesion. Brain Research. 279: 1-8. PMID 6416611 DOI: 10.1016/0006-8993(83)90157-9  0.437
1983 Kozlowski MR, Neve KA, Grisham JE, Marshall JF. Chronic lithium administration alters behavioral recovery from nigrostriatal injury: effects on neostriatal [3H]spiroperidol binding sites. Brain Research. 267: 301-11. PMID 6409351 DOI: 10.1016/0006-8993(83)90882-X  0.473
1983 Marshall JF, Drew MC, Neve KA. Recovery of function after mesotelencephalic dopaminergic injury in senescence. Brain Research. 259: 249-60. PMID 6297672 DOI: 10.1016/0006-8993(83)91255-6  0.478
1982 Neve KA, Kozlowski MR, Marshall JF. Plasticity of neostriatal dopamine receptors after nigrostriatal injury: relationship to recovery of sensorimotor functions and behavioral supersensitivity. Brain Research. 244: 33-44. PMID 6288182 DOI: 10.1016/0006-8993(82)90901-5  0.579
Show low-probability matches.